A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin

Inclusion Criteria

• •1. Healthy male and female participants ≥18 and ≤60 years, at the time of signing the informed consent.
• •2. Body mass index (BMI) ≥18.5 and ≤30.0 kg/m\^2.
• •3. Female participants of childbearing potential agree to undergo pregnancy tests, and if with a non-vasectomized nor infertile male partner, agree to use an appropriate method of contraception (i.e., abstinence, hormonal, intrauterine device, bilateral tubal occlusion).
• •4. No clinically relevant diseases captured in medical history.
• •5. No clinically relevant abnormalities on physical examination.
• •6. No clinically relevant abnormalities on vital signs.
• •7. No clinically relevant abnormalities on 12-lead electrocardiogram (ECG).
• •8. No clinically relevant abnormalities on clinical laboratory tests.
• •9. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) above the upper limit of normal range (ULN).
• •10. Estimated renal creatinine clearance (CrCl) above the lower limit of normal range, based on creatinine clearance calculation by the Cockcroft-Gault formula and normalized to an average body surface area of 1.73 m\^2.
• •11. Willingness to accept and comply with all study procedures and restrictions.
• •12. Non-smoker or ex-smoker (i.e., someone who abstained from using tobacco- or nicotine-containing products for at least 3 months prior to Screening).
• •13. Ability to comprehend and willingness to freely sign the informed consent.